British Journal of Haematology

Papers
(The H4-Index of British Journal of Haematology is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
e‐Posters126
Graham Serjeant, Sickle Cell, Jamaica and Beyond: A Life, Ian Randle Publishers (Kingston and Miami), 202193
Don't forget cord blood in non‐remission acute myeloid leukaemia!87
Issue Information81
Issue Information81
Correction to “Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients”72
61
How to dose and monitor argatroban for treatment of HIT59
Issue Information58
Clinical perspectives on post‐induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation55
CAR T in patients with large B‐cell lymphoma not fit for autologous transplant54
Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data54
Erythrophagocytosis in a patient with myelodysplastic syndrome with excess blasts‐1 with isolated del(6q)51
Haematopoietic stem cell mobilisation followed by high‐dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma50
Applying current smouldering myeloma risk models to a UK single‐centre cohort and clinical features at progression47
The impact of COVID‐19 vaccination on patients with a history of heparin‐induced thrombocytopenia44
The significance of mixed chimaerism and cell lineage chimaerism monitoring in paediatric patients post haematopoietic stem cell transplant42
Stratified management based on surface antibody for the prevention of hepatitis B virus reactivation in lymphoma patients42
Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma – A study from the Danish Lymphoma Registry40
Myelodysplastic syndrome associated‐haemophagocytic lymphohistiocytosis: A retrospective study of 15 cases in a single centre39
Functional impairment of erythropoiesis in Congenital Dyserythropoietic Anaemia type I arises at the progenitor level39
Venetoclax ramp‐up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study38
Antibody response to a third SARS‐CoV‐2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation38
Use of dipyridamole is associated with lower risk of lymphoid neoplasms: a propensity score‐matched cohort study37
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia37
Liquid biopsy in Hodgkin lymphoma – moving beyond the proof of principle36
Immune‐mediated thrombocytopenia and IL‐6‐mediated thrombocytosis observed in idiopathic multicentric Castleman disease35
Phase Ib study of eltrombopag and azacitidine in patients with high‐risk myelodysplastic syndromes and related disorders (the ELASTIC study)34
Patient preferences in the treatment of stage III/IV classic Hodgkin lymphoma: Results from the CONNECT cross‐sectional survey33
Management of immunosuppression in post‐transplant lymphoproliferative disorders treated with CAR T cells33
Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti‐leukaemic potential and alloreactivity across major human leukoc32
Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L‐ASP: A retrospective analysis with an ASP‐based protocol in adult patients with acute lympho31
Management of luspatercept therapy in patients with transfusion‐dependent β‐thalassaemia31
The oldest case of lymphoma? Insights from a XIII century fresco31
A novel PML germline variant as a candidate predisposing genetic aberration in familial acute myeloid leukaemia31
0.1849730014801